The brain faces multiple threats to cognitive health: age-related degeneration, neuroinflammation, oxidative stress, proteotoxicity (misfolded proteins), and stem cell exhaustion. Neuropeptides offer multi-targeted approaches to maintaining cognition, protecting neurons from damage, and reversing early cognitive decline. This guide explores BDNF signalling, neuroprotection mechanisms, and research applications in cognitive enhancement and neurodegeneration prevention.
Cognitive Decline Crisis
- ~55 million people globally with dementia
- Alzheimer’s disease accounts for 60–80% of dementia cases
- Current Alzheimer’s treatments offer minimal benefit
- Cognitive decline begins decades before symptom onset
- Prevention/early intervention most promising approach
Key Brain Ageing Mechanisms
- Amyloid-β Accumulation: Protein aggregation in Alzheimer’s disease
- Tau Pathology: Neurofibrillary tangles; associated with cognitive decline
- Neuroinflammation: Microglia activation, pro-inflammatory cytokines
- Oxidative Stress: ROS accumulation; insufficient antioxidant defence
- Mitochondrial Dysfunction: Impaired ATP production; exacerbates ROS
- Proteotoxicity: Protein misfolding and aggregation
- Loss of Synaptic Plasticity: Reduced learning capacity
- Neurogenesis Decline: Reduced new neuron formation in hippocampus
Peptide Approaches to Neuroprotection
- BDNF Upregulation (Semax, Selank): Enhance neuronal survival and plasticity
- Anti-Inflammatory (BPC-157, KPV, Selank): Reduce neuroinflammation
- Antioxidant (SS-31, Epithalon): Reduce ROS
- Mitochondrial Support (SS-31, MOTS-C): Restore energy production
- Growth Factor Signalling (Colivelin, Dihexa): Activate neuroprotective pathways
- Neurogenesis Enhancement (Semax, IGF-1): Promote new neuron formation
The Science of Cognitive Health & Decline
BDNF: The Master Neurotrophin
BDNF (brain-derived neurotrophic factor) is arguably the most important molecule for brain health:
- Neuronal Survival: Prevents apoptosis (cell death)
- Growth: Promotes dendrite and axon growth
- Plasticity: Enhances synaptic strength and formation (LTP, long-term potentiation)
- Memory: Required for consolidation (conversion of short-term to long-term memory)
- Neurogenesis: Promotes new neuron formation in hippocampus
- Antidepressant-Like: BDNF levels correlate with mood; low BDNF in depression
BDNF-TrkB Signalling Cascade: [As detailed in Neuropeptides guide]
Semax & BDNF:
- Direct transcriptional enhancement of BDNF gene
- CREB activation (phosphorylation and nuclear entry)
- Result: ↑ BDNF mRNA, ↑ BDNF protein in brain
- Effects persist after discontinuation (positive feedback loop)
Neuroinflammation & Neurodegeneration
Chronic neuroinflammation drives neurodegeneration:
Microglia Activation:
- Microglia are brain immune cells; normally in resting state
- Pro-inflammatory stimuli (amyloid-β, misfolded tau, LPS) activate microglia
- Activated microglia produce TNF-α, IL-6, IL-1β, ROS
- Chronic activation causes neuronal damage
Neuroinflammatory Cascade:
- Pathogenic stimulus (amyloid, tau, ischemia, trauma)
- Microglia activation
- ↑ Pro-inflammatory cytokines (TNF-α, IL-6, IL-1β)
- Neuronal mitochondrial stress
- ↑ ROS (reactive oxygen species)
- Neuronal apoptosis and synaptic loss
- Cognitive decline
Anti-Inflammatory Peptides:
Synaptic Plasticity & Learning
Learning and memory require synaptic plasticity — the ability of synapses to strengthen or weaken based on activity patterns.
Long-Term Potentiation (LTP):
- Persistent increase in synaptic transmission strength
- Molecular basis of memory formation
- Requires NMDA and AMPA receptor involvement
- BDNF critical for LTP induction and maintenance
- Calcium influx → gene expression → structural changes
Age-Related Plasticity Decline:
- LTP magnitude decreases with age
- Requires higher calcium/stimulation to induce LTP
- BDNF levels decline
- Synaptic density decreases
Neuropeptide Enhancement:
- Semax/Selank ↑ BDNF → enhanced LTP
- Improved learning capacity and memory consolidation
- Reversal of age-related plasticity decline
Neurogenesis in Adult Brain
Neurogenesis (birth of new neurons) occurs throughout life in two brain regions:
- Subventricular Zone (SVZ): New neurons → olfactory bulb
- Dentate Gyrus (DG) of hippocampus: New neurons → memory processing
Adult Neurogenesis Process:
- Neural stem cells proliferate
- Differentiate into neurons
- Migrate to target location
- Integrate into existing circuits
- Contribute to learning and memory
Decline with Age:
- Neurogenesis rates drop ~80% from young to old
- Partially reversed by BDNF, IGF-1, exercise
Peptide Enhancement:
- Semax ↑ hippocampal neurogenesis via BDNF
- IGF-1 ↑ neural stem cell proliferation and neuronal differentiation
- Result: Improved learning capacity, memory resilience
Relevant Peptides for Neuroprotection & Cognitive Research
Table: Peptides for Brain Health
| Peptide | Primary Mechanism | Cognitive Effect | Neuroprotection | Research Application | Typical Dose |
|---|---|---|---|---|---|
| Semax | BDNF ↑ | Memory ↑, focus ↑ | Broad | Cognitive enhancement, neurodegeneration | 0.1–0.5 mg/day |
| Selank | BDNF ↑, GABAergic | Anxiety ↓, calm focus | Anti-inflammatory | Stress resilience, cognitive + mood | 0.1–0.5 mg/day |
| DSIP | Sleep regulation | Sleep quality ↑ | Stress protective | Sleep-based neuroprotection | 0.2–0.5 mg/kg |
| Colivelin | STAT3 pathway | Neuroprotection | Anti-inflammatory, anti-amyloid | Alzheimer’s models | 0.1–0.5 mg/kg |
| Dihexa | HGF/c-Met | Memory, synaptic | BDNF-independent neuroprotection | Cognitive enhancement, Alzheimer’s | 0.01–0.1 mg/kg |
| BPC-157 | VEGF-like, anti-inflam | Recovery ↑ | Anti-inflammatory, angiogenic | Stroke, TBI recovery | 0.1–1 mg/kg/day |
| Epithalon | Telomerase, antioxidant | Brain ageing ↓ | Senescence reversal | Anti-ageing cognitive | 10–50 mg/dose |
| IGF-1 LR3 | IGF-1R agonism | Learning ↑ | Neuroprotection, neurogenesis | Cognitive, neurodegeneration | 0.1–1 mg/kg/day |
| NAD+ | Sirtuin activation | Energy ↑, cognition | Mitochondrial, anti-inflammatory | Neurodegeneration, ageing | 250–1000 mg/day |
Neurotrophic Peptide Mixtures
| Compound | Composition | Approx. MW Range | Primary Research Target | Source |
|---|---|---|---|---|
| Cerebrolysin | Heterogeneous peptide/amino acid mixture | <10,000 Da fragments | TrkB, neurotrophic signalling pathways | Enzymatic hydrolysate of porcine brain tissue |
All figures are approximate and sourced from published literature; researchers should confirm exact specifications against current certificates of analysis.
Comparisons with Similar Peptides
Semax vs. Selank: Both share the same Pro-Gly-Pro stabilising motif and originate from the same Russian research programme, but their parent sequences point them toward different primary research applications — Semax toward cognitive/neuroprotective research via its ACTH-fragment origin, and Selank toward anxiolytic and immunomodulatory research via its tuftsin origin. In practice, their researched effects overlap considerably, and they are sometimes studied in combination.
Cerebrolysin vs. single-molecule neurotrophic peptides: Cerebrolysin’s defining characteristic — and limitation — is its heterogeneity. Single-molecule peptides like Semax or Dihexa allow for more precise mechanistic attribution, while Cerebrolysin’s mixture-based composition reflects an attempt to approximate the broad, multi-target action of natural neurotrophic processes, at the cost of mechanistic specificity.
Dihexa vs. classical neurotrophic factors (BDNF, NGF): Direct administration of neurotrophic factors like BDNF is hampered by poor blood-brain barrier penetration and short half-life. Dihexa is studied specifically because it is reported to replicate downstream synaptogenic signalling at far smaller, more bioavailable doses — making it a more tractable experimental tool than the native growth factors themselves.
FAQ
What’s the difference between a neuropeptide and a neurotransmitter? Neurotransmitters are typically small molecules synthesised locally at the synapse for fast, direct signalling. Neuropeptides are larger, synthesised from precursor proteins, often act over longer timescales, and tend to modulate rather than directly trigger neuronal activity.
Why does Semax retain CNS activity but not ACTH’s hormonal effects? Because the modification removes the C-terminal sequence responsible for melanocortin receptor binding (where ACTH’s classical hormonal activity originates), while preserving the N-terminal region implicated in central nervous system effects.
Is Cerebrolysin a single peptide? No — it’s a standardised mixture of multiple peptide fragments and free amino acids derived from porcine brain tissue, which distinguishes it mechanistically from single-molecule peptides like Semax or Dihexa.
What does “Pro-Gly-Pro” do in Semax and Selank? It’s a stabilising tripeptide extension added to the parent sequence (ACTH fragment for Semax, tuftsin for Selank) to increase resistance to enzymatic degradation, extending the peptide’s functional activity in research models.
Why is Dihexa studied for synaptogenesis specifically? Because its proposed mechanism — potentiating HGF/c-Met receptor signalling — is reported in preclinical literature to promote new synapse formation at very low concentrations, distinguishing it from peptides primarily studied for neuroprotection or neurotransmitter modulation.
External Resources
- PubMed: search terms “Semax ACTH fragment CNS,” “Selank tuftsin anxiolytic,” “Cerebrolysin neurotrophic mechanism,” “Dihexa HGF c-Met synaptogenesis”
- UniProt entries for BDNF (P23560) and NGF (P01138)
- Journal of Neurochemistry and Neuropharmacology — primary literature on neuropeptide signalling pathways
- Institute of Molecular Genetics (Moscow) — original research programme background for Semax and Selank
This guide is provided for educational and research-reference purposes only. The compounds discussed are intended strictly for laboratory and in vitro research applications by qualified professionals. Nothing in this guide constitutes medical, dosing, or usage advice for human or animal administration.